A European research consortium led by DZNE will be investigating the neurodegenerative disease “Spinocerebellar Ataxia Type 3” (SCA3) in collaboration with the French pharmaceutical company Servier Laboratories.
In individuals with a genetic predisposition to Alzheimer’s disease, the immune cells of the brain – the “microglia” – start exerting a protective effect up to two decades before the first symptoms appear.
A study by DZNE and the University Hospital Bonn suggests that assessments of the eye’s retina could help to detect a loss of brain substance, i. e. “brain atrophy”.
DZNE scientist Markus Zweckstetter has been awarded 150,000 euros by the European Research Council to test potential drugs against Alzheimer’s disease in laboratory studies.
Findings by DZNE researchers and partners support the view that hyperactive immune cells in the brain can have a protective effect in the course of neurodegenerative diseases.
A consortium led by DZNE has been tasked with investigating whether patients with “dementia of unclear etiology” benefit from examination of the brain using amyloid PET.
Welcome to our website, here you can inform yourself basically cookie-free.
We would be pleased if you would allow a cookie to be set for analysis purposes in order to optimise our provided information. All data are pseudonymous and are only used by the DZNE. We deliberately avoid third-party cookies. You can deselect this setting at any time here.
